RemeGen Co., Ltd. — Capital/Financing Update 2021

Jun 11, 2021

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [169 x 52] intentionally omitted <==

RemeGen Co., Ltd. 榮昌生物製藥（煙台）股份有限公司*

(A joint stock company incorporated in the People’s Republic of China with limited liability) (Stock Code: 9995)

ANNOUNCEMENT REGARDING H SHARE FULL CIRCULATION PROGRESS OF COMPLETION

Reference is made to the announcements (the “ Announcements ”) of RemeGen Co., Ltd.* 榮昌 生物製藥（煙台）股份有限公司 (the “ Company ”) dated March 25, 2021, May 10, 2021, May 17, 2021 and June 2, 2021 in relation to the H share full circulation program of the Company.

Unless otherwise indicated, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcements.

The Company has completed the application to China Clearing, Shenzhen Branch and maintains a detailed record of the initial holding of the 9,045,695 Converted H Shares held by the relevant holders. The application for a domestic transaction commission code and abbreviation (domestic transaction commission code: 299918; abbreviation: 榮昌生物) submitted by the Company has been confirmed by China Clearing, Shenzhen Branch pursuant to the authorization of the Shenzhen Stock Exchange. The Participating Shareholders who are PRC nationals will establish specified fund accounts for H Share “Full Circulation” at Huatai Securities and will activate access right for domestic transactions.

The participating domestic shareholders may conduct trading of the Converted H Shares upon completion of the onshore arrangement procedures as set out in the paragraph headed “Conversion and Trading Procedures” in the announcement of the Company dated May 17, 2021.

By order of the Board RemeGen Co., Ltd. Mr. Wang Weidong Chairman and executive director

Yantai, The People’s Republic of China June 11, 2021

As at the date of this announcement, the Board of the Company comprises Mr. Wang Weidong, Dr. Fang Jianmin, Dr. He Ruyi and Mr. Lin Jian as the executive directors, Dr. Wang Liqiang and Dr. Su Xiaodi as the non-executive directors, and Ms. Yu Shanshan, Mr. Hao Xianjing and Dr. Ma Lan as the independent non-executive directors.